[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sglt2-inhibitor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sglt2-inhibitor":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100652650","phase-4-clinical-impact-of-sglt2-inhibitor-after-dc-cardioversion-in-persistent-af-with-hfpef-100652650",false,"NCT07776054","Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF","Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent Atrial Fibrillation Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥19 years\n* Persistent atrial fibrillation\n* H2FPEF score ≥6 or HFA-PEFF score ≥5\n* Restoration of sinus rhythm after electrical cardioversion\n\nExclusion Criteria:\n\n* Previous use of an SGLT2 inhibitor\n* Intracardiac thrombus on transesophageal echocardiography\n* Refusal to participate","ALL","19 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.",[26,27,28],"Atrial Fibrillation","SGLT2 Inhibitor","DC Cardioversion","RECRUITING","2026-08-17",{"date":32,"type":33},"2026-08-20","ACTUAL",{"date":35,"type":33},"2024-02-01",{"date":37,"type":20},"2027-09-01",{"name":39,"class":40},"Samsung Medical Center","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100580531","incidence-characterisation-and-outcome-relevance-of-perioperative-sglt2-inhibitor-associated-ketoacidosis-100580531","NCT06838507","Incidence, Characterisation and Outcome-relevance of Perioperative SGLT2 Inhibitor Associated Ketoacidosis","Incidence, Characterisation and Outcome-relevance of Perioperative SGLT2 Inhibitor Associated Ketoacidosis - A Multicentre Prospective Cohort Study","Inclusion Criteria:\n\n* Prescription and regular intakte of any SGLT2 inhibitor within the last three months (regardless if SGLT2 inhibitor was discontinued preoperatively or not)\n* Surgical procedure\n* At least one overnight stay in the hospital following surgery\n* Age \\>= 18 years\n\nExclusion Criteria:\n\n* Unwilling and\u002For unable to consent\n* Outpatient surgery","18 Years",{"count":51,"type":20},2000,"OBSERVATIONAL","The goal of this observational study is to generate data on the incidence and outcome-relevance of sodium-glucose cotransporter 2 (SGLT2) inhibitor associated ketoacidosis in adult patients with regular intake of any SGLT2 inhibitor within the last three months that are undergoing in-patient surgery. Further, it will describe strategies in current clinical practice to prevent and manage SGLT2 inhibitor associated ketoacidosis. The specific aims of this study are:\n\n1. To assess the incidence of SGLT2 inhibitor associated ketoacidosis in surgical patients\n2. To characterise fasting times in patients with SGLT2 inhibitor associated ketoacidosis\n3. To describe the management of SGLT2 inhibitor associated ketoacidosis in current clinical practice\n4. To assess the outcome impact of SGLT2 inhibitor associated ketoacidosis",[27,55],"Ketoacidosis, Eugylcemic","NOT_YET_RECRUITING","2025-02-17",{"date":59,"type":33},"2025-02-20",{"date":61,"type":20},"2025-04",{"date":63,"type":20},"2026-12",{"name":65,"class":40},"Heinrich-Heine University, Duesseldorf"]